BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31777606)

  • 1. Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer.
    Zhang N; Chen S; Wu L; Wu Y; Jiang G; Shao J; Chen L; Sun J; Na R; Wang X; Xu J
    J Cancer; 2019; 10(26):6761-6766. PubMed ID: 31777606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.
    van Kessel KE; Van Neste L; Lurkin I; Zwarthoff EC; Van Criekinge W
    J Urol; 2016 Mar; 195(3):601-7. PubMed ID: 26327355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
    Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
    Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of molecular analyses in voided urine for the assessment of patients with hematuria.
    Beukers W; Kandimalla R; van Houwelingen D; Kovacic H; Chin JF; Lingsma HF; Dyrskjot L; Zwarthoff EC
    PLoS One; 2013; 8(10):e77657. PubMed ID: 24143252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese.
    Wang Y; Yu Y; Ye R; Zhang D; Li Q; An D; Fang L; Lin Y; Hou Y; Xu A; Fu Y; Lu W; Chen X; Chen M; Zhang M; Jiang H; Zhang C; Dong P; Li C; Chen J; Yang G; Liu C; Cai Z; Zhou F; Wu S
    Oncotarget; 2016 Jan; 7(3):2754-64. PubMed ID: 26700620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
    Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical performance and utility of a DNA methylation urine test for bladder cancer.
    Abern MR; Owusu R; Inman BA
    Urol Oncol; 2014 Jan; 32(1):51.e21-6. PubMed ID: 24360662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.
    Reinert T; Modin C; Castano FM; Lamy P; Wojdacz TK; Hansen LL; Wiuf C; Borre M; Dyrskjøt L; Orntoft TF
    Clin Cancer Res; 2011 Sep; 17(17):5582-92. PubMed ID: 21788354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
    Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
    Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
    Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
    Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
    Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
    Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
    Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
    PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study.
    García-Baquero R; Puerta P; Beltran M; Alvarez M; Sacristan R; Alvarez-Ossorio JL; Sánchez-Carbayo M
    J Urol; 2013 Aug; 190(2):723-30. PubMed ID: 23485510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of bladder cancer using urinary cell-free DNA and cellular DNA.
    Ou Z; Li K; Yang T; Dai Y; Chandra M; Ning J; Wang Y; Xu R; Gao T; Xie Y; He Q; Li Y; Lu Q; Wang L; Song Z
    Clin Transl Med; 2020 Jan; 9(1):4. PubMed ID: 31938901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
    Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Kang HW; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
    Urol Oncol; 2019 Jan; 37(1):86-96. PubMed ID: 30446454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.